A

s Brexit nears and the European Medicines Agency prepares to move its headquarters from London, the regulator warned it could lose gobs of employees and, depending upon the new location, may no longer be able to function. But even the loss of just 15 percent of its staff would require at least a two-year recovery.

The dire forecast, which emerged from a survey of approximately 900 EMA employees, found more than 70 percent of the staff would leave if the agency relocated to eight of 19 cities that are being considered for its new headquarters. Under this scenario, the agency warned such an exodus would have “important consequences for public health in the European Union.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If I worked in London, I would want to go somewhere comparable culturally. So this is not only unsurprising, it seems bluntly obvious without needing a survey for confirmation.
    why does it need to be monolithic? Couldn’t some functions be done in different locations? What about working remotely (for some)?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy